[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fD610HrlACeopnwfTtzMQC6eZtY__V8dnE9dIV-KMlm4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":56,"rows":63},"Pacira Pharmaceuticals, Inc",[4],102,false,6,23,18813,5,21,[14,17,20,23,25,27,30,32],{"name":15,"count":16},"Postoperative Pain",14,{"name":18,"count":19},"Pain",10,{"name":21,"count":22},"Osteoarthritis of the Knee",9,{"name":24,"count":8},"Postoperative Pain Management",{"name":26,"count":11},"Bunion",{"name":28,"count":29},"Pain Management",4,{"name":31,"count":29},"Bowel Obstruction",{"name":33,"count":34},"Facial Wrinkles",3,[36,41,46,51],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04119687","Study to Evaluate the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee","2023-11-28","FX201",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06269705","ZILRETTA in Subjects With Shoulder Osteoarthritis","2026-12","ZILRETTA",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06271265","Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery","2027-01","EXPAREL",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT06884865","A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee","2032-07","Enekinragene Inzadenovec",[57,58,59,60,61,62],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[64,101,122,333,387,409,519,579,601,623,654,672,699,717,735,753,778,796,814,840,858,876,894,912,936,954,972,996,1014,1032,1054,1072,1098,1116,1196,1301,1354,1385,1419,1455,1488,1506,1524,1542,1560,1584,1602,1620,1650,1672,1694,1716,1734,1752,1770,1792,1810,1835,1853,1871,1889,1913,1931,1956,1974,1996,2023,2046,2064,2082,2100,2118],{"intervention":45,"totalTrials":65,"cells":66},2,{"EARLY_PHASE1":67,"PHASE1":70,"PHASE2":72,"PHASE3":87,"PHASE4":97,"NA":99},{"trials":68,"activeCount":69},[],0,{"trials":71,"activeCount":69},[],{"trials":73,"activeCount":69},[74],{"nctId":75,"briefTitle":76,"status":77,"phases":78,"primaryCompletion":79,"completion":79,"start":80,"enrollment":81,"conditions":82,"interventions":84},"NCT06977568","A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip","TERMINATED",[59],"2025-10-16","2025-07-25",1,[83],"Osteoarthritis of Hip",[85,86],"Zilretta","Triamcinolone Acetonide",{"trials":88,"activeCount":81,"soonestReadout":44},[89],{"nctId":42,"briefTitle":43,"status":90,"phases":91,"primaryCompletion":44,"completion":44,"start":92,"enrollment":93,"conditions":94,"interventions":96},"ACTIVE_NOT_RECRUITING",[60],"2024-02-05",150,[95],"Glenohumeral Osteoarthritis",[45],{"trials":98,"activeCount":69},[],{"trials":100,"activeCount":69},[],{"intervention":55,"totalTrials":81,"cells":102},{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":116,"PHASE4":118,"NA":120},{"trials":104,"activeCount":69},[],{"trials":106,"activeCount":69},[],{"trials":108,"activeCount":81,"soonestReadout":54},[109],{"nctId":52,"briefTitle":53,"status":90,"phases":110,"primaryCompletion":54,"completion":54,"start":111,"enrollment":112,"conditions":113,"interventions":115},[59],"2025-02-26",135,[114],"Osteoarthritis (OA) of the Knee",[55],{"trials":117,"activeCount":69},[],{"trials":119,"activeCount":69},[],{"trials":121,"activeCount":69},[],{"intervention":50,"totalTrials":123,"cells":124},20,{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":185,"PHASE3":187,"PHASE4":214,"NA":331},{"trials":126,"activeCount":69},[],{"trials":128,"activeCount":81,"soonestReadout":49},[129,139,150,158,166,176],{"nctId":130,"briefTitle":131,"status":77,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":123,"conditions":135,"interventions":137},"NCT04173611","Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers",[58],"2020-12-07","2020-06-08",[136],"Healthy",[50,138],"Bupivacaine Hydrochloride",{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT02210247","Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers","COMPLETED",[58],"2014-09","2014-08",60,[148],"Healthy Volunteers",[50],{"nctId":151,"briefTitle":152,"status":77,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":11,"conditions":156,"interventions":157},"NCT03428984","Study in Adult Subjects Undergoing Posterolateral Thoracotomy",[58],"2018-09-28","2018-05-03",[24],[50],{"nctId":47,"briefTitle":48,"status":159,"phases":160,"primaryCompletion":49,"completion":49,"start":161,"enrollment":162,"conditions":163,"interventions":164},"RECRUITING",[58],"2024-03-29",48,[15],[50,165],"bupivacaine",{"nctId":167,"briefTitle":168,"status":142,"phases":169,"primaryCompletion":170,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":175},"NCT02985762","PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery",[58],"2017-09","2016-12",15,[174,28],"Spinal Fusion",[50],{"nctId":177,"briefTitle":178,"status":142,"phases":179,"primaryCompletion":180,"completion":180,"start":181,"enrollment":172,"conditions":182,"interventions":183},"NCT03485014","Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL",[58],"2019-02-12","2018-04-10",[24],[184],"Exparel",{"trials":186,"activeCount":69},[],{"trials":188,"activeCount":69},[189,200],{"nctId":190,"briefTitle":191,"status":142,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},"NCT03682302","Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL",[60],"2019-08-30","2019-09-24","2019-04-02",98,[24],[184,199],"0.5% Bupivacaine HCl",{"nctId":201,"briefTitle":202,"status":142,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":213},"NCT04518462","Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries",[60],"2021-04-05","2020-10-20",121,[208,26,209,210,211,212],"Lower Extremity Surgery","Metatarsophalangeal Fushion","Midfoot Fusion","Hindfoot Fushion","Total Ankle Arthroplasty",[184,138],{"trials":215,"activeCount":69},[216,224,235,244,256,266,276,285,293,303,312,321],{"nctId":217,"briefTitle":218,"status":77,"phases":219,"primaryCompletion":220,"completion":220,"start":221,"enrollment":81,"conditions":222,"interventions":223},"NCT01919606","EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy",[61],"2012-10","2012-08",[15],[50],{"nctId":225,"briefTitle":226,"status":142,"phases":227,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":233},"NCT02142829","Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball",[61],"2013-03","2012-11",101,[232],"Obesity",[50,234],"On-Q Pain Ball",{"nctId":236,"briefTitle":237,"status":142,"phases":238,"primaryCompletion":239,"completion":240,"start":145,"enrollment":241,"conditions":242,"interventions":243},"NCT02199574","Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy",[61],"2015-04","2015-06",12,[18],[50],{"nctId":245,"briefTitle":246,"status":247,"phases":248,"primaryCompletion":249,"completion":249,"start":250,"enrollment":69,"conditions":251,"interventions":254},"NCT03955458","EXPAREL Facia Iliaca Compartment Block for Intertrochanteric Hip Fracture","WITHDRAWN",[61],"2020-05","2019-08-26",[252,253],"Hip Fractures","Intertrochanteric Fractures",[50,255,138],"Ropivacaine",{"nctId":257,"briefTitle":258,"status":142,"phases":259,"primaryCompletion":260,"completion":260,"start":261,"enrollment":262,"conditions":263,"interventions":264},"NCT02713490","Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty",[61],"2017-02-08","2016-04-18",140,[18],[50,265],"Bupivacaine",{"nctId":267,"briefTitle":268,"status":142,"phases":269,"primaryCompletion":220,"completion":220,"start":270,"enrollment":271,"conditions":272,"interventions":274},"NCT01509807","A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B504",[61],"2012-01",33,[273],"Retraction of Colostomy",[275,50],"IV morphine sulfate or Sponsor-approved equivalent",{"nctId":277,"briefTitle":278,"status":77,"phases":279,"primaryCompletion":280,"completion":280,"start":281,"enrollment":11,"conditions":282,"interventions":283},"NCT01507233","A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302",[61],"2012-07","2012-05",[31],[284,50],"IV morphine sulfate",{"nctId":286,"briefTitle":287,"status":142,"phases":288,"primaryCompletion":280,"completion":221,"start":289,"enrollment":290,"conditions":291,"interventions":292},"NCT01507246","Adult Patients Undergoing Open Colectomy MA402S23B303",[61],"2011-12",42,[31],[284,50],{"nctId":294,"briefTitle":295,"status":142,"phases":296,"primaryCompletion":297,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NCT01801124","EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair",[61],"2012-12","2012-04",13,[301],"Hernia",[50],{"nctId":304,"briefTitle":305,"status":77,"phases":306,"primaryCompletion":307,"completion":308,"start":289,"enrollment":309,"conditions":310,"interventions":311},"NCT02058290","A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy",[61],"2012-09","2013-02",122,[31],[275,50],{"nctId":313,"briefTitle":314,"status":77,"phases":315,"primaryCompletion":240,"completion":316,"start":317,"enrollment":241,"conditions":318,"interventions":319},"NCT02353754","Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section",[61],"2015-07","2015-05",[18],[320,50],"Intrathecal morphine",{"nctId":322,"briefTitle":323,"status":77,"phases":324,"primaryCompletion":325,"completion":326,"start":327,"enrollment":328,"conditions":329,"interventions":330},"NCT01919190","EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries",[61],"2013-12","2014-02","2013-08",67,[18],[50],{"trials":332,"activeCount":69},[],{"intervention":265,"totalTrials":11,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":385},{"trials":336,"activeCount":69},[],{"trials":338,"activeCount":81,"soonestReadout":49},[339,349,359],{"nctId":340,"briefTitle":341,"status":142,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT04002089","Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy",[58],"2019-12-02","2019-07-26",45,[26],[348,265],"Exparel Injectable Product",{"nctId":350,"briefTitle":351,"status":142,"phases":352,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":356,"interventions":357},"NCT05456490","Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers",[58],"2025-02-27","2023-04-18",54,[136],[358,265],"Liposomal Bupivacaine 13.3",{"nctId":47,"briefTitle":48,"status":159,"phases":360,"primaryCompletion":49,"completion":49,"start":161,"enrollment":162,"conditions":361,"interventions":362},[58],[15],[50,165],{"trials":364,"activeCount":69},[],{"trials":366,"activeCount":69},[],{"trials":368,"activeCount":69},[369,373],{"nctId":257,"briefTitle":258,"status":142,"phases":370,"primaryCompletion":260,"completion":260,"start":261,"enrollment":262,"conditions":371,"interventions":372},[61],[18],[50,265],{"nctId":374,"briefTitle":375,"status":142,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},"NCT03176459","Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections",[61],"2018-11-20","2018-12-04","2017-06-01",186,[382,28],"C-Section",[384,265],"Exparel + Bupivacaine",{"trials":386,"activeCount":69},[],{"intervention":40,"totalTrials":81,"cells":388},{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":401,"PHASE3":403,"PHASE4":405,"NA":407},{"trials":390,"activeCount":69},[],{"trials":392,"activeCount":81,"soonestReadout":39},[393],{"nctId":37,"briefTitle":38,"status":90,"phases":394,"primaryCompletion":39,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":400},[58],"2026-11-28","2020-03-02",72,[399],"Osteoarthritis, Knee",[40],{"trials":402,"activeCount":69},[],{"trials":404,"activeCount":69},[],{"trials":406,"activeCount":69},[],{"trials":408,"activeCount":69},[],{"intervention":410,"totalTrials":19,"cells":411},"Bupivacaine HCl",{"EARLY_PHASE1":412,"PHASE1":414,"PHASE2":416,"PHASE3":465,"PHASE4":505,"NA":517},{"trials":413,"activeCount":69},[],{"trials":415,"activeCount":69},[],{"trials":417,"activeCount":69},[418,430,440,449,456],{"nctId":419,"briefTitle":420,"status":142,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":428},"NCT01203644","Evaluation of the Safety, Efficacy, and Pharmacokinetics of SKY0402 in Subjects Undergoing Inguinal Hernia Repair",[59],"2006-01","2006-12","2004-12",76,[427],"Inguinal Hernia",[429,410],"SKY0402",{"nctId":431,"briefTitle":432,"status":142,"phases":433,"primaryCompletion":434,"completion":435,"start":436,"enrollment":437,"conditions":438,"interventions":439},"NCT00529126","Phase 2 Dose-Ranging Study of SKY0402 for Prolonged Postoperative Analgesia in Subject Undergoing Hemorrhoidectomy",[59],"2007-12","2008-07","2007-09",100,[15],[429,410],{"nctId":441,"briefTitle":442,"status":142,"phases":443,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":448},"NCT00485693","Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty",[59],"2009-08","2007-06",138,[15],[410,429],{"nctId":450,"briefTitle":451,"status":142,"phases":452,"primaryCompletion":434,"completion":453,"start":445,"enrollment":196,"conditions":454,"interventions":455},"NCT00485433","Dose-ranging Study for Postoperative Analgesia in Subjects Undergoing Primary Unilateral Inguinal Hernia Repair",[59],"2008-08",[15],[410,429],{"nctId":457,"briefTitle":458,"status":142,"phases":459,"primaryCompletion":460,"completion":423,"start":461,"enrollment":462,"conditions":463,"interventions":464},"NCT01206595","Safety, Efficacy, and Pharmacokinetics of SKY0402 Administered as a Nerve Block in Subjects Undergoing Bunionectomy",[59],"2006-03","2005-03",58,[15],[429,410],{"trials":466,"activeCount":69},[467,476,484,492],{"nctId":468,"briefTitle":469,"status":77,"phases":470,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":475},"NCT00813111","Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation",[60],"2009-02","2008-11",136,[18],[429,410],{"nctId":477,"briefTitle":478,"status":142,"phases":479,"primaryCompletion":471,"completion":471,"start":453,"enrollment":480,"conditions":481,"interventions":483},"NCT00744848","Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy",[60],204,[482],"Hemorrhoids",[410,429],{"nctId":485,"briefTitle":486,"status":142,"phases":487,"primaryCompletion":488,"completion":471,"start":453,"enrollment":489,"conditions":490,"interventions":491},"NCT00745290","A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty",[60],"2009-01",245,[15],[410,429],{"nctId":493,"briefTitle":494,"status":142,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":502},"NCT05157841","Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy",[60],"2022-08-17","2022-02-15",185,[500,501],"Bunionectomy","Hallux Valgus",[503,410,504],"Bupivacaine liposome injectable suspension 266 mg","Bupivacaine liposome injectable suspension 133 mg",{"trials":506,"activeCount":69},[507],{"nctId":508,"briefTitle":509,"status":77,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":515},"NCT03015961","Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery",[61],"2017-10-30","2017-02-21",38,[24],[516,410],"EXPAREL and bupivacaine HCl",{"trials":518,"activeCount":69},[],{"intervention":138,"totalTrials":8,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":540,"PHASE3":542,"PHASE4":571,"NA":577},{"trials":522,"activeCount":69},[],{"trials":524,"activeCount":69},[525,529],{"nctId":130,"briefTitle":131,"status":77,"phases":526,"primaryCompletion":133,"completion":133,"start":134,"enrollment":123,"conditions":527,"interventions":528},[58],[136],[50,138],{"nctId":530,"briefTitle":531,"status":142,"phases":532,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":539},"NCT04293809","Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation",[58],"2020-01-15","2020-01-29","2019-12-19",30,[538],"Breast Augmentation",[348,138],{"trials":541,"activeCount":69},[],{"trials":543,"activeCount":69},[544,556,567],{"nctId":545,"briefTitle":546,"status":247,"phases":547,"primaryCompletion":548,"completion":548,"start":549,"enrollment":69,"conditions":550,"interventions":554},"NCT03954639","Phase 3, Randomized, Double Blinded, Active Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL Admixed With Bupi vs. Bupi Only Administered as Combined Sciatic and Adductor Canal Nerve Block for Postsurgical Analgesia in Lower Extremity Surgeries",[60],"2020-09","2020-06-15",[26,551,210,552,212,553],"Metatarsophalangeal Fusion","Hindfoot Fusion","Forefoot Surgery",[555,138],"EXPAREL 13.3Mg\u002FmL Suspension for",{"nctId":557,"briefTitle":558,"status":142,"phases":559,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":563,"interventions":565},"NCT05139030","Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty",[60],"2022-07-11","2022-01-18",167,[564,28],"Knee Osteoarthritis",[566,138],"bupivacaine liposome injectable suspension",{"nctId":201,"briefTitle":202,"status":142,"phases":568,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":569,"interventions":570},[60],[208,26,209,210,211,212],[184,138],{"trials":572,"activeCount":69},[573],{"nctId":245,"briefTitle":246,"status":247,"phases":574,"primaryCompletion":249,"completion":249,"start":250,"enrollment":69,"conditions":575,"interventions":576},[61],[252,253],[50,255,138],{"trials":578,"activeCount":69},[],{"intervention":275,"totalTrials":65,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":589,"NA":599},{"trials":582,"activeCount":69},[],{"trials":584,"activeCount":69},[],{"trials":586,"activeCount":69},[],{"trials":588,"activeCount":69},[],{"trials":590,"activeCount":69},[591,595],{"nctId":267,"briefTitle":268,"status":142,"phases":592,"primaryCompletion":220,"completion":220,"start":270,"enrollment":271,"conditions":593,"interventions":594},[61],[273],[275,50],{"nctId":304,"briefTitle":305,"status":77,"phases":596,"primaryCompletion":307,"completion":308,"start":289,"enrollment":309,"conditions":597,"interventions":598},[61],[31],[275,50],{"trials":600,"activeCount":69},[],{"intervention":284,"totalTrials":65,"cells":602},{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":621},{"trials":604,"activeCount":69},[],{"trials":606,"activeCount":69},[],{"trials":608,"activeCount":69},[],{"trials":610,"activeCount":69},[],{"trials":612,"activeCount":69},[613,617],{"nctId":277,"briefTitle":278,"status":77,"phases":614,"primaryCompletion":280,"completion":280,"start":281,"enrollment":11,"conditions":615,"interventions":616},[61],[31],[284,50],{"nctId":286,"briefTitle":287,"status":142,"phases":618,"primaryCompletion":280,"completion":221,"start":289,"enrollment":290,"conditions":619,"interventions":620},[61],[31],[284,50],{"trials":622,"activeCount":69},[],{"intervention":624,"totalTrials":65,"cells":625},"EXPAREL Infiltration",{"EARLY_PHASE1":626,"PHASE1":628,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":652},{"trials":627,"activeCount":69},[],{"trials":629,"activeCount":69},[],{"trials":631,"activeCount":69},[],{"trials":633,"activeCount":69},[],{"trials":635,"activeCount":69},[636,645],{"nctId":637,"briefTitle":638,"status":142,"phases":639,"primaryCompletion":640,"completion":640,"start":641,"enrollment":172,"conditions":642,"interventions":643},"NCT02284386","Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty",[61],"2015-03","2014-12",[18],[644,624],"Bupivacaine SNB",{"nctId":646,"briefTitle":647,"status":142,"phases":648,"primaryCompletion":640,"completion":640,"start":144,"enrollment":9,"conditions":649,"interventions":650},"NCT02255500","EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty",[61],[18],[651,624],"Bupivacaine FNB",{"trials":653,"activeCount":69},[],{"intervention":234,"totalTrials":81,"cells":655},{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":664,"NA":670},{"trials":657,"activeCount":69},[],{"trials":659,"activeCount":69},[],{"trials":661,"activeCount":69},[],{"trials":663,"activeCount":69},[],{"trials":665,"activeCount":69},[666],{"nctId":225,"briefTitle":226,"status":142,"phases":667,"primaryCompletion":228,"completion":228,"start":229,"enrollment":230,"conditions":668,"interventions":669},[61],[232],[50,234],{"trials":671,"activeCount":69},[],{"intervention":673,"totalTrials":81,"cells":674},"50 mcg Duramorph+ EXPAREL + multi-modal pain regimen",{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":697},{"trials":676,"activeCount":69},[],{"trials":678,"activeCount":69},[],{"trials":680,"activeCount":69},[],{"trials":682,"activeCount":69},[],{"trials":684,"activeCount":69},[685],{"nctId":686,"briefTitle":687,"status":142,"phases":688,"primaryCompletion":689,"completion":690,"start":691,"enrollment":562,"conditions":692,"interventions":694},"NCT03853694","Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section",[61],"2020-01-09","2020-01-16","2019-03-04",[693,28],"Elective Cesarean Section",[673,695,696],"150 mcg Duramorph + multi-modal pain regimen","Exparel TAP + multi-modal pain regimen",{"trials":698,"activeCount":69},[],{"intervention":695,"totalTrials":81,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":709,"NA":715},{"trials":702,"activeCount":69},[],{"trials":704,"activeCount":69},[],{"trials":706,"activeCount":69},[],{"trials":708,"activeCount":69},[],{"trials":710,"activeCount":69},[711],{"nctId":686,"briefTitle":687,"status":142,"phases":712,"primaryCompletion":689,"completion":690,"start":691,"enrollment":562,"conditions":713,"interventions":714},[61],[693,28],[673,695,696],{"trials":716,"activeCount":69},[],{"intervention":696,"totalTrials":81,"cells":718},{"EARLY_PHASE1":719,"PHASE1":721,"PHASE2":723,"PHASE3":725,"PHASE4":727,"NA":733},{"trials":720,"activeCount":69},[],{"trials":722,"activeCount":69},[],{"trials":724,"activeCount":69},[],{"trials":726,"activeCount":69},[],{"trials":728,"activeCount":69},[729],{"nctId":686,"briefTitle":687,"status":142,"phases":730,"primaryCompletion":689,"completion":690,"start":691,"enrollment":562,"conditions":731,"interventions":732},[61],[693,28],[673,695,696],{"trials":734,"activeCount":69},[],{"intervention":255,"totalTrials":81,"cells":736},{"EARLY_PHASE1":737,"PHASE1":739,"PHASE2":741,"PHASE3":743,"PHASE4":745,"NA":751},{"trials":738,"activeCount":69},[],{"trials":740,"activeCount":69},[],{"trials":742,"activeCount":69},[],{"trials":744,"activeCount":69},[],{"trials":746,"activeCount":69},[747],{"nctId":245,"briefTitle":246,"status":247,"phases":748,"primaryCompletion":249,"completion":249,"start":250,"enrollment":69,"conditions":749,"interventions":750},[61],[252,253],[50,255,138],{"trials":752,"activeCount":69},[],{"intervention":754,"totalTrials":81,"cells":755},"EXPAREL and Bupivacaine",{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":762,"PHASE4":764,"NA":776},{"trials":757,"activeCount":69},[],{"trials":759,"activeCount":69},[],{"trials":761,"activeCount":69},[],{"trials":763,"activeCount":69},[],{"trials":765,"activeCount":69},[766],{"nctId":767,"briefTitle":768,"status":77,"phases":769,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":773,"interventions":774},"NCT03927911","Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries",[61],"2020-08-04","2019-07-31",65,[24],[754,775],"Standard of Care",{"trials":777,"activeCount":69},[],{"intervention":775,"totalTrials":81,"cells":779},{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":794},{"trials":781,"activeCount":69},[],{"trials":783,"activeCount":69},[],{"trials":785,"activeCount":69},[],{"trials":787,"activeCount":69},[],{"trials":789,"activeCount":69},[790],{"nctId":767,"briefTitle":768,"status":77,"phases":791,"primaryCompletion":770,"completion":770,"start":771,"enrollment":772,"conditions":792,"interventions":793},[61],[24],[754,775],{"trials":795,"activeCount":69},[],{"intervention":384,"totalTrials":81,"cells":797},{"EARLY_PHASE1":798,"PHASE1":800,"PHASE2":802,"PHASE3":804,"PHASE4":806,"NA":812},{"trials":799,"activeCount":69},[],{"trials":801,"activeCount":69},[],{"trials":803,"activeCount":69},[],{"trials":805,"activeCount":69},[],{"trials":807,"activeCount":69},[808],{"nctId":374,"briefTitle":375,"status":142,"phases":809,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":810,"interventions":811},[61],[382,28],[384,265],{"trials":813,"activeCount":69},[],{"intervention":815,"totalTrials":81,"cells":816},"Intrathecal (injected into the spinal fluid) DepoCyt",{"EARLY_PHASE1":817,"PHASE1":819,"PHASE2":821,"PHASE3":823,"PHASE4":825,"NA":838},{"trials":818,"activeCount":69},[],{"trials":820,"activeCount":69},[],{"trials":822,"activeCount":69},[],{"trials":824,"activeCount":69},[],{"trials":826,"activeCount":69},[827],{"nctId":828,"briefTitle":829,"status":142,"phases":830,"completion":831,"start":832,"enrollment":437,"conditions":833,"interventions":835},"NCT00029523","DepoCyt Therapy in Patients With Neoplastic Meningitis From Lymphoma or a Solid Tumor",[61],"2004-11","2001-04",[834],"Meningeal Neoplasms",[815,836,837],"Intrathecal methotrexate","Intrathecal cytarabine",{"trials":839,"activeCount":69},[],{"intervention":836,"totalTrials":81,"cells":841},{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":856},{"trials":843,"activeCount":69},[],{"trials":845,"activeCount":69},[],{"trials":847,"activeCount":69},[],{"trials":849,"activeCount":69},[],{"trials":851,"activeCount":69},[852],{"nctId":828,"briefTitle":829,"status":142,"phases":853,"completion":831,"start":832,"enrollment":437,"conditions":854,"interventions":855},[61],[834],[815,836,837],{"trials":857,"activeCount":69},[],{"intervention":837,"totalTrials":81,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":866,"PHASE4":868,"NA":874},{"trials":861,"activeCount":69},[],{"trials":863,"activeCount":69},[],{"trials":865,"activeCount":69},[],{"trials":867,"activeCount":69},[],{"trials":869,"activeCount":69},[870],{"nctId":828,"briefTitle":829,"status":142,"phases":871,"completion":831,"start":832,"enrollment":437,"conditions":872,"interventions":873},[61],[834],[815,836,837],{"trials":875,"activeCount":69},[],{"intervention":644,"totalTrials":81,"cells":877},{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":884,"PHASE4":886,"NA":892},{"trials":879,"activeCount":69},[],{"trials":881,"activeCount":69},[],{"trials":883,"activeCount":69},[],{"trials":885,"activeCount":69},[],{"trials":887,"activeCount":69},[888],{"nctId":637,"briefTitle":638,"status":142,"phases":889,"primaryCompletion":640,"completion":640,"start":641,"enrollment":172,"conditions":890,"interventions":891},[61],[18],[644,624],{"trials":893,"activeCount":69},[],{"intervention":651,"totalTrials":81,"cells":895},{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":902,"PHASE4":904,"NA":910},{"trials":897,"activeCount":69},[],{"trials":899,"activeCount":69},[],{"trials":901,"activeCount":69},[],{"trials":903,"activeCount":69},[],{"trials":905,"activeCount":69},[906],{"nctId":646,"briefTitle":647,"status":142,"phases":907,"primaryCompletion":640,"completion":640,"start":144,"enrollment":9,"conditions":908,"interventions":909},[61],[18],[651,624],{"trials":911,"activeCount":69},[],{"intervention":913,"totalTrials":81,"cells":914},"Instillation - EXPAREL",{"EARLY_PHASE1":915,"PHASE1":917,"PHASE2":919,"PHASE3":921,"PHASE4":923,"NA":934},{"trials":916,"activeCount":69},[],{"trials":918,"activeCount":69},[],{"trials":920,"activeCount":69},[],{"trials":922,"activeCount":69},[],{"trials":924,"activeCount":69},[925],{"nctId":926,"briefTitle":927,"status":142,"phases":928,"primaryCompletion":229,"completion":229,"start":298,"enrollment":929,"conditions":930,"interventions":932},"NCT01582490","Study of EXPAREL in Patients Undergoing Breast Augmentation",[61],19,[931,15],"Mammoplasty",[913,933],"Infiltration - EXPAREL",{"trials":935,"activeCount":69},[],{"intervention":933,"totalTrials":81,"cells":937},{"EARLY_PHASE1":938,"PHASE1":940,"PHASE2":942,"PHASE3":944,"PHASE4":946,"NA":952},{"trials":939,"activeCount":69},[],{"trials":941,"activeCount":69},[],{"trials":943,"activeCount":69},[],{"trials":945,"activeCount":69},[],{"trials":947,"activeCount":69},[948],{"nctId":926,"briefTitle":927,"status":142,"phases":949,"primaryCompletion":229,"completion":229,"start":298,"enrollment":929,"conditions":950,"interventions":951},[61],[931,15],[913,933],{"trials":953,"activeCount":69},[],{"intervention":516,"totalTrials":81,"cells":955},{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":970},{"trials":957,"activeCount":69},[],{"trials":959,"activeCount":69},[],{"trials":961,"activeCount":69},[],{"trials":963,"activeCount":69},[],{"trials":965,"activeCount":69},[966],{"nctId":508,"briefTitle":509,"status":77,"phases":967,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":968,"interventions":969},[61],[24],[516,410],{"trials":971,"activeCount":69},[],{"intervention":973,"totalTrials":81,"cells":974},"Group 1 Standard of Care",{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":994},{"trials":976,"activeCount":69},[],{"trials":978,"activeCount":69},[],{"trials":980,"activeCount":69},[],{"trials":982,"activeCount":69},[],{"trials":984,"activeCount":69},[985],{"nctId":986,"briefTitle":987,"status":142,"phases":988,"primaryCompletion":220,"completion":220,"start":989,"enrollment":990,"conditions":991,"interventions":992},"NCT01509638","A Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal MA402S23B501",[61],"2012-03",47,[273],[973,993],"Group 2 EXPAREL",{"trials":995,"activeCount":69},[],{"intervention":993,"totalTrials":81,"cells":997},{"EARLY_PHASE1":998,"PHASE1":1000,"PHASE2":1002,"PHASE3":1004,"PHASE4":1006,"NA":1012},{"trials":999,"activeCount":69},[],{"trials":1001,"activeCount":69},[],{"trials":1003,"activeCount":69},[],{"trials":1005,"activeCount":69},[],{"trials":1007,"activeCount":69},[1008],{"nctId":986,"briefTitle":987,"status":142,"phases":1009,"primaryCompletion":220,"completion":220,"start":989,"enrollment":990,"conditions":1010,"interventions":1011},[61],[273],[973,993],{"trials":1013,"activeCount":69},[],{"intervention":320,"totalTrials":81,"cells":1015},{"EARLY_PHASE1":1016,"PHASE1":1018,"PHASE2":1020,"PHASE3":1022,"PHASE4":1024,"NA":1030},{"trials":1017,"activeCount":69},[],{"trials":1019,"activeCount":69},[],{"trials":1021,"activeCount":69},[],{"trials":1023,"activeCount":69},[],{"trials":1025,"activeCount":69},[1026],{"nctId":313,"briefTitle":314,"status":77,"phases":1027,"primaryCompletion":240,"completion":316,"start":317,"enrollment":241,"conditions":1028,"interventions":1029},[61],[18],[320,50],{"trials":1031,"activeCount":69},[],{"intervention":1033,"totalTrials":81,"cells":1034},"morphine sulfate",{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1052},{"trials":1036,"activeCount":69},[],{"trials":1038,"activeCount":69},[],{"trials":1040,"activeCount":69},[],{"trials":1042,"activeCount":69},[],{"trials":1044,"activeCount":69},[1045],{"nctId":1046,"briefTitle":1047,"status":77,"phases":1048,"primaryCompletion":280,"completion":280,"start":989,"enrollment":65,"conditions":1049,"interventions":1050},"NCT01507220","A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B301",[61],[31],[1033,1051],"bupivacaine liposome extended-release injectable suspension",{"trials":1053,"activeCount":69},[],{"intervention":1051,"totalTrials":81,"cells":1055},{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1062,"PHASE4":1064,"NA":1070},{"trials":1057,"activeCount":69},[],{"trials":1059,"activeCount":69},[],{"trials":1061,"activeCount":69},[],{"trials":1063,"activeCount":69},[],{"trials":1065,"activeCount":69},[1066],{"nctId":1046,"briefTitle":1047,"status":77,"phases":1067,"primaryCompletion":280,"completion":280,"start":989,"enrollment":65,"conditions":1068,"interventions":1069},[61],[31],[1033,1051],{"trials":1071,"activeCount":69},[],{"intervention":1073,"totalTrials":81,"cells":1074},"EXPAREL 20 mL",{"EARLY_PHASE1":1075,"PHASE1":1077,"PHASE2":1079,"PHASE3":1081,"PHASE4":1083,"NA":1096},{"trials":1076,"activeCount":69},[],{"trials":1078,"activeCount":69},[],{"trials":1080,"activeCount":69},[],{"trials":1082,"activeCount":69},[],{"trials":1084,"activeCount":69},[1085],{"nctId":1086,"briefTitle":1087,"status":142,"phases":1088,"primaryCompletion":281,"completion":280,"start":989,"enrollment":1089,"conditions":1090,"interventions":1094},"NCT01582477","TAP-patients With Robotic Assisted Lap Prostatectomy",[61],24,[1091,1092,1093],"Postsurgical Pain","Analgesia","Prostatectomy",[1073,1095],"EXPAREL 40 mL",{"trials":1097,"activeCount":69},[],{"intervention":1095,"totalTrials":81,"cells":1099},{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1106,"PHASE4":1108,"NA":1114},{"trials":1101,"activeCount":69},[],{"trials":1103,"activeCount":69},[],{"trials":1105,"activeCount":69},[],{"trials":1107,"activeCount":69},[],{"trials":1109,"activeCount":69},[1110],{"nctId":1086,"briefTitle":1087,"status":142,"phases":1111,"primaryCompletion":281,"completion":280,"start":989,"enrollment":1089,"conditions":1112,"interventions":1113},[61],[1091,1092,1093],[1073,1095],{"trials":1115,"activeCount":69},[],{"intervention":429,"totalTrials":241,"cells":1117},{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1138,"PHASE3":1160,"PHASE4":1192,"NA":1194},{"trials":1119,"activeCount":69},[],{"trials":1121,"activeCount":69},[1122,1130],{"nctId":1123,"briefTitle":1124,"status":142,"phases":1125,"primaryCompletion":471,"completion":471,"start":1126,"enrollment":1127,"conditions":1128,"interventions":1129},"NCT00806806","Evaluate the Onset of Action of SKY0402 Following Local Infiltration in Healthy Volunteers",[58],"2008-10",128,[24],[429],{"nctId":1131,"briefTitle":1132,"status":142,"phases":1133,"primaryCompletion":1134,"completion":1134,"start":445,"enrollment":162,"conditions":1135,"interventions":1136},"NCT00485667","Phase 1 Thorough QT Study in Young Healthy Volunteers",[58],"2007-08",[15],[429,1137],"Moxifloxacin 400mg",{"trials":1139,"activeCount":69},[1140,1144,1148,1152,1156],{"nctId":419,"briefTitle":420,"status":142,"phases":1141,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":1142,"interventions":1143},[59],[427],[429,410],{"nctId":431,"briefTitle":432,"status":142,"phases":1145,"primaryCompletion":434,"completion":435,"start":436,"enrollment":437,"conditions":1146,"interventions":1147},[59],[15],[429,410],{"nctId":441,"briefTitle":442,"status":142,"phases":1149,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":1150,"interventions":1151},[59],[15],[410,429],{"nctId":450,"briefTitle":451,"status":142,"phases":1153,"primaryCompletion":434,"completion":453,"start":445,"enrollment":196,"conditions":1154,"interventions":1155},[59],[15],[410,429],{"nctId":457,"briefTitle":458,"status":142,"phases":1157,"primaryCompletion":460,"completion":423,"start":461,"enrollment":462,"conditions":1158,"interventions":1159},[59],[15],[429,410],{"trials":1161,"activeCount":69},[1162,1166,1175,1179,1183],{"nctId":468,"briefTitle":469,"status":77,"phases":1163,"primaryCompletion":471,"completion":471,"start":472,"enrollment":473,"conditions":1164,"interventions":1165},[60],[18],[429,410],{"nctId":1167,"briefTitle":1168,"status":142,"phases":1169,"primaryCompletion":1170,"completion":1170,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1174},"NCT00890682","Study of Postoperative Analgesia in Bunionectomy",[60],"2009-11","2009-04",193,[26,501],[429],{"nctId":477,"briefTitle":478,"status":142,"phases":1176,"primaryCompletion":471,"completion":471,"start":453,"enrollment":480,"conditions":1177,"interventions":1178},[60],[482],[410,429],{"nctId":485,"briefTitle":486,"status":142,"phases":1180,"primaryCompletion":488,"completion":471,"start":453,"enrollment":489,"conditions":1181,"interventions":1182},[60],[15],[410,429],{"nctId":1184,"briefTitle":1185,"status":142,"phases":1186,"primaryCompletion":1170,"completion":1170,"start":1187,"enrollment":1188,"conditions":1189,"interventions":1191},"NCT00890721","Study of Pain Control in Hemorrhoidectomy",[60],"2009-05",189,[1190],"Hemorrhoid",[429],{"trials":1193,"activeCount":69},[],{"trials":1195,"activeCount":69},[],{"intervention":1197,"totalTrials":22,"cells":1198},"FX006 32 mg",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1276,"PHASE4":1297,"NA":1299},{"trials":1200,"activeCount":69},[],{"trials":1202,"activeCount":69},[],{"trials":1204,"activeCount":69},[1205,1215,1225,1235,1245,1256,1267],{"nctId":1206,"briefTitle":1207,"status":77,"phases":1208,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":8,"conditions":1211,"interventions":1213},"NCT02468583","Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee",[59],"2016-07","2015-02",[1212],"Post-traumatic Osteoarthritis of the Knee",[1197,1214],"TCA IR 40 mg",{"nctId":1216,"briefTitle":1217,"status":142,"phases":1218,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1222,"interventions":1223},"NCT02116972","Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee",[59],"2015-11","2014-04",310,[21],[1197,1224],"FX006 16 mg",{"nctId":1226,"briefTitle":1227,"status":142,"phases":1228,"primaryCompletion":1229,"completion":1230,"start":1231,"enrollment":271,"conditions":1232,"interventions":1234},"NCT02762370","Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes",[59],"2016-10","2016-11","2016-04",[21,1233],"Type 2 Diabetes Mellitus",[1197,1214],{"nctId":1236,"briefTitle":1237,"status":142,"phases":1238,"primaryCompletion":1239,"completion":1239,"start":1240,"enrollment":1089,"conditions":1241,"interventions":1243},"NCT03378076","Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA",[59],"2018-03-14","2017-12-06",[1242],"Bilateral Knee Osteoarthritis",[1197,1244],"TAcs 40 mg",{"nctId":1246,"briefTitle":1247,"status":142,"phases":1248,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1255},"NCT03382262","Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip",[59],"2018-10-09","2017-12-18",55,[1253,1254],"Osteoarthritis of the Shoulder","Osteoarthritis of the Hip",[1197,1244],{"nctId":1257,"briefTitle":1258,"status":142,"phases":1259,"primaryCompletion":1260,"completion":1261,"start":1262,"enrollment":1263,"conditions":1264,"interventions":1266},"NCT04065074","Study to Evaluate a Procedure for Intra-articular Injection of FX006 in Patients With Osteoarthritis of the Hip",[59],"2019-10-11","2019-12-30","2019-07-30",16,[1265],"Osteoarthritis, Hip",[1197],{"nctId":1268,"briefTitle":1269,"status":142,"phases":1270,"primaryCompletion":1271,"completion":1271,"start":1219,"enrollment":1272,"conditions":1273,"interventions":1274},"NCT02637323","Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee",[59],"2016-09",81,[21],[1197,1275],"TCA IR 40",{"trials":1277,"activeCount":69},[1278,1288],{"nctId":1279,"briefTitle":1280,"status":142,"phases":1281,"primaryCompletion":1282,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1287},"NCT03529942","Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee",[60],"2019-11-08","2020-03-09","2018-04-24",129,[399],[1197],{"nctId":1289,"briefTitle":1290,"status":142,"phases":1291,"primaryCompletion":1292,"completion":1292,"start":1293,"enrollment":1294,"conditions":1295,"interventions":1296},"NCT03046446","Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee",[60],"2018-07-19","2017-02-20",208,[21],[1197],{"trials":1298,"activeCount":69},[],{"trials":1300,"activeCount":69},[],{"intervention":1302,"totalTrials":29,"cells":1303},"FX006",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1329,"PHASE4":1350,"NA":1352},{"trials":1305,"activeCount":69},[],{"trials":1307,"activeCount":69},[],{"trials":1309,"activeCount":69},[1310,1320],{"nctId":1311,"briefTitle":1312,"status":142,"phases":1313,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1318},"NCT01487161","Study of FX006 in Patients With Osteoarthritis of the Knee",[59],"2013-04","2012-06",229,[21],[1302,1319],"TCA IR",{"nctId":1321,"briefTitle":1322,"status":77,"phases":1323,"primaryCompletion":549,"completion":549,"start":1324,"enrollment":929,"conditions":1325,"interventions":1327},"NCT04160091","Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis",[59],"2019-11-07",[1253,1326],"Adhesive Capsulitis",[1302,1328],"Normal Saline",{"trials":1330,"activeCount":69},[1331,1340],{"nctId":1332,"briefTitle":1333,"status":142,"phases":1334,"primaryCompletion":1335,"completion":1335,"start":1336,"enrollment":1337,"conditions":1338,"interventions":1339},"NCT02357459","Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee",[60],"2016-01","2015-01",486,[21],[1302,1275],{"nctId":1341,"briefTitle":1342,"status":77,"phases":1343,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1346,"conditions":1347,"interventions":1348},"NCT03793010","Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis",[60],"2019-08-07","2018-12-12",70,[1265],[1302,1349],"Normal saline",{"trials":1351,"activeCount":69},[],{"trials":1353,"activeCount":69},[],{"intervention":1275,"totalTrials":34,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1375,"PHASE4":1381,"NA":1383},{"trials":1357,"activeCount":69},[],{"trials":1359,"activeCount":69},[],{"trials":1361,"activeCount":69},[1362,1371],{"nctId":1363,"briefTitle":1364,"status":142,"phases":1365,"primaryCompletion":229,"completion":229,"start":280,"enrollment":1089,"conditions":1366,"interventions":1367},"NCT01487200","Pharmacokinetic and Pharmacodynamic Study of FX006 in Patients With Osteoarthritis of the Knee",[59],[21],[1368,1369,1370,1275],"FX006 10 mg","FX006 40 mg","FX006 60 mg",{"nctId":1268,"briefTitle":1269,"status":142,"phases":1372,"primaryCompletion":1271,"completion":1271,"start":1219,"enrollment":1272,"conditions":1373,"interventions":1374},[59],[21],[1197,1275],{"trials":1376,"activeCount":69},[1377],{"nctId":1332,"briefTitle":1333,"status":142,"phases":1378,"primaryCompletion":1335,"completion":1335,"start":1336,"enrollment":1337,"conditions":1379,"interventions":1380},[60],[21],[1302,1275],{"trials":1382,"activeCount":69},[],{"trials":1384,"activeCount":69},[],{"intervention":1328,"totalTrials":34,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1403,"PHASE3":1409,"PHASE4":1415,"NA":1417},{"trials":1388,"activeCount":69},[],{"trials":1390,"activeCount":69},[1391],{"nctId":1392,"briefTitle":1393,"status":142,"phases":1394,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":1398,"conditions":1399,"interventions":1401},"NCT04826328","Study to Evaluate the Safety and Tolerability of FX301 in Patients Undergoing Bunionectomy",[58],"2022-01-11","2022-03-30","2021-03-15",85,[1400,26],"Pain, Postoperative",[1402,1328],"FX301",{"trials":1404,"activeCount":69},[1405],{"nctId":1321,"briefTitle":1322,"status":77,"phases":1406,"primaryCompletion":549,"completion":549,"start":1324,"enrollment":929,"conditions":1407,"interventions":1408},[59],[1253,1326],[1302,1328],{"trials":1410,"activeCount":69},[1411],{"nctId":1341,"briefTitle":1342,"status":77,"phases":1412,"primaryCompletion":1344,"completion":1344,"start":1345,"enrollment":1346,"conditions":1413,"interventions":1414},[60],[1265],[1302,1349],{"trials":1416,"activeCount":69},[],{"trials":1418,"activeCount":69},[],{"intervention":566,"totalTrials":34,"cells":1420},{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1427,"PHASE4":1451,"NA":1453},{"trials":1422,"activeCount":69},[],{"trials":1424,"activeCount":69},[],{"trials":1426,"activeCount":69},[],{"trials":1428,"activeCount":69},[1429,1433,1442],{"nctId":557,"briefTitle":558,"status":142,"phases":1430,"primaryCompletion":560,"completion":560,"start":561,"enrollment":562,"conditions":1431,"interventions":1432},[60],[564,28],[566,138],{"nctId":1434,"briefTitle":1435,"status":142,"phases":1436,"primaryCompletion":1437,"completion":1437,"start":1438,"enrollment":1439,"conditions":1440,"interventions":1441},"NCT02713178","Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty",[60],"2017-06-30","2016-06-03",232,[18],[566],{"nctId":1443,"briefTitle":1444,"status":142,"phases":1445,"primaryCompletion":1446,"completion":1446,"start":1447,"enrollment":1448,"conditions":1449,"interventions":1450},"NCT02713230","Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery",[60],"2017-07-07","2016-05-09",156,[18],[566,566],{"trials":1452,"activeCount":69},[],{"trials":1454,"activeCount":69},[],{"intervention":1456,"totalTrials":65,"cells":1457},"EXPAREL 266 mg",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1462,"PHASE3":1464,"PHASE4":1484,"NA":1486},{"trials":1459,"activeCount":69},[],{"trials":1461,"activeCount":69},[],{"trials":1463,"activeCount":69},[],{"trials":1465,"activeCount":69},[1466,1475],{"nctId":1467,"briefTitle":1468,"status":142,"phases":1469,"primaryCompletion":1470,"completion":1470,"start":297,"enrollment":1471,"conditions":1472,"interventions":1474},"NCT01802411","Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy",[60],"2013-06",191,[1473,15],"Posterolateral Thoracotomy",[1456],{"nctId":1476,"briefTitle":1477,"status":142,"phases":1478,"primaryCompletion":325,"completion":325,"start":307,"enrollment":1479,"conditions":1480,"interventions":1481},"NCT01683071","Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty",[59,60],297,[15],[1482,1483,1456],"EXPAREL 67 mg","EXPAREL 133 mg",{"trials":1485,"activeCount":69},[],{"trials":1487,"activeCount":69},[],{"intervention":199,"totalTrials":81,"cells":1489},{"EARLY_PHASE1":1490,"PHASE1":1492,"PHASE2":1494,"PHASE3":1496,"PHASE4":1502,"NA":1504},{"trials":1491,"activeCount":69},[],{"trials":1493,"activeCount":69},[],{"trials":1495,"activeCount":69},[],{"trials":1497,"activeCount":69},[1498],{"nctId":190,"briefTitle":191,"status":142,"phases":1499,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":1500,"interventions":1501},[60],[24],[184,199],{"trials":1503,"activeCount":69},[],{"trials":1505,"activeCount":69},[],{"intervention":555,"totalTrials":81,"cells":1507},{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1512,"PHASE3":1514,"PHASE4":1520,"NA":1522},{"trials":1509,"activeCount":69},[],{"trials":1511,"activeCount":69},[],{"trials":1513,"activeCount":69},[],{"trials":1515,"activeCount":69},[1516],{"nctId":545,"briefTitle":546,"status":247,"phases":1517,"primaryCompletion":548,"completion":548,"start":549,"enrollment":69,"conditions":1518,"interventions":1519},[60],[26,551,210,552,212,553],[555,138],{"trials":1521,"activeCount":69},[],{"trials":1523,"activeCount":69},[],{"intervention":503,"totalTrials":81,"cells":1525},{"EARLY_PHASE1":1526,"PHASE1":1528,"PHASE2":1530,"PHASE3":1532,"PHASE4":1538,"NA":1540},{"trials":1527,"activeCount":69},[],{"trials":1529,"activeCount":69},[],{"trials":1531,"activeCount":69},[],{"trials":1533,"activeCount":69},[1534],{"nctId":493,"briefTitle":494,"status":142,"phases":1535,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":1536,"interventions":1537},[60],[500,501],[503,410,504],{"trials":1539,"activeCount":69},[],{"trials":1541,"activeCount":69},[],{"intervention":504,"totalTrials":81,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1548,"PHASE3":1550,"PHASE4":1556,"NA":1558},{"trials":1545,"activeCount":69},[],{"trials":1547,"activeCount":69},[],{"trials":1549,"activeCount":69},[],{"trials":1551,"activeCount":69},[1552],{"nctId":493,"briefTitle":494,"status":142,"phases":1553,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":1554,"interventions":1555},[60],[500,501],[503,410,504],{"trials":1557,"activeCount":69},[],{"trials":1559,"activeCount":69},[],{"intervention":1561,"totalTrials":81,"cells":1562},"Bupivacaine liposome",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1567,"PHASE3":1569,"PHASE4":1580,"NA":1582},{"trials":1564,"activeCount":69},[],{"trials":1566,"activeCount":69},[],{"trials":1568,"activeCount":69},[],{"trials":1570,"activeCount":69},[1571],{"nctId":1572,"briefTitle":1573,"status":142,"phases":1574,"primaryCompletion":1335,"completion":1335,"start":1575,"enrollment":1576,"conditions":1577,"interventions":1579},"NCT02517905","Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction",[60],"2015-08",166,[1578],"Dental Pain",[1561],{"trials":1581,"activeCount":69},[],{"trials":1583,"activeCount":69},[],{"intervention":1482,"totalTrials":81,"cells":1585},{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1590,"PHASE3":1592,"PHASE4":1598,"NA":1600},{"trials":1587,"activeCount":69},[],{"trials":1589,"activeCount":69},[],{"trials":1591,"activeCount":69},[],{"trials":1593,"activeCount":69},[1594],{"nctId":1476,"briefTitle":1477,"status":142,"phases":1595,"primaryCompletion":325,"completion":325,"start":307,"enrollment":1479,"conditions":1596,"interventions":1597},[59,60],[15],[1482,1483,1456],{"trials":1599,"activeCount":69},[],{"trials":1601,"activeCount":69},[],{"intervention":1483,"totalTrials":81,"cells":1603},{"EARLY_PHASE1":1604,"PHASE1":1606,"PHASE2":1608,"PHASE3":1610,"PHASE4":1616,"NA":1618},{"trials":1605,"activeCount":69},[],{"trials":1607,"activeCount":69},[],{"trials":1609,"activeCount":69},[],{"trials":1611,"activeCount":69},[1612],{"nctId":1476,"briefTitle":1477,"status":142,"phases":1613,"primaryCompletion":325,"completion":325,"start":307,"enrollment":1479,"conditions":1614,"interventions":1615},[59,60],[15],[1482,1483,1456],{"trials":1617,"activeCount":69},[],{"trials":1619,"activeCount":69},[],{"intervention":1214,"totalTrials":34,"cells":1621},{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1644,"PHASE4":1646,"NA":1648},{"trials":1623,"activeCount":69},[],{"trials":1625,"activeCount":69},[],{"trials":1627,"activeCount":69},[1628,1636,1640],{"nctId":1629,"briefTitle":1630,"status":142,"phases":1631,"primaryCompletion":1220,"completion":1220,"start":1632,"enrollment":1633,"conditions":1634,"interventions":1635},"NCT02003365","Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee",[59],"2013-11",50,[21],[1368,1369,1214],{"nctId":1206,"briefTitle":1207,"status":77,"phases":1637,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":8,"conditions":1638,"interventions":1639},[59],[1212],[1197,1214],{"nctId":1226,"briefTitle":1227,"status":142,"phases":1641,"primaryCompletion":1229,"completion":1230,"start":1231,"enrollment":271,"conditions":1642,"interventions":1643},[59],[21,1233],[1197,1214],{"trials":1645,"activeCount":69},[],{"trials":1647,"activeCount":69},[],{"trials":1649,"activeCount":69},[],{"intervention":1368,"totalTrials":65,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1666,"PHASE4":1668,"NA":1670},{"trials":1653,"activeCount":69},[],{"trials":1655,"activeCount":69},[],{"trials":1657,"activeCount":69},[1658,1662],{"nctId":1629,"briefTitle":1630,"status":142,"phases":1659,"primaryCompletion":1220,"completion":1220,"start":1632,"enrollment":1633,"conditions":1660,"interventions":1661},[59],[21],[1368,1369,1214],{"nctId":1363,"briefTitle":1364,"status":142,"phases":1663,"primaryCompletion":229,"completion":229,"start":280,"enrollment":1089,"conditions":1664,"interventions":1665},[59],[21],[1368,1369,1370,1275],{"trials":1667,"activeCount":69},[],{"trials":1669,"activeCount":69},[],{"trials":1671,"activeCount":69},[],{"intervention":1369,"totalTrials":65,"cells":1673},{"EARLY_PHASE1":1674,"PHASE1":1676,"PHASE2":1678,"PHASE3":1688,"PHASE4":1690,"NA":1692},{"trials":1675,"activeCount":69},[],{"trials":1677,"activeCount":69},[],{"trials":1679,"activeCount":69},[1680,1684],{"nctId":1629,"briefTitle":1630,"status":142,"phases":1681,"primaryCompletion":1220,"completion":1220,"start":1632,"enrollment":1633,"conditions":1682,"interventions":1683},[59],[21],[1368,1369,1214],{"nctId":1363,"briefTitle":1364,"status":142,"phases":1685,"primaryCompletion":229,"completion":229,"start":280,"enrollment":1089,"conditions":1686,"interventions":1687},[59],[21],[1368,1369,1370,1275],{"trials":1689,"activeCount":69},[],{"trials":1691,"activeCount":69},[],{"trials":1693,"activeCount":69},[],{"intervention":1244,"totalTrials":65,"cells":1695},{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1710,"PHASE4":1712,"NA":1714},{"trials":1697,"activeCount":69},[],{"trials":1699,"activeCount":69},[],{"trials":1701,"activeCount":69},[1702,1706],{"nctId":1236,"briefTitle":1237,"status":142,"phases":1703,"primaryCompletion":1239,"completion":1239,"start":1240,"enrollment":1089,"conditions":1704,"interventions":1705},[59],[1242],[1197,1244],{"nctId":1246,"briefTitle":1247,"status":142,"phases":1707,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":1251,"conditions":1708,"interventions":1709},[59],[1253,1254],[1197,1244],{"trials":1711,"activeCount":69},[],{"trials":1713,"activeCount":69},[],{"trials":1715,"activeCount":69},[],{"intervention":1319,"totalTrials":81,"cells":1717},{"EARLY_PHASE1":1718,"PHASE1":1720,"PHASE2":1722,"PHASE3":1728,"PHASE4":1730,"NA":1732},{"trials":1719,"activeCount":69},[],{"trials":1721,"activeCount":69},[],{"trials":1723,"activeCount":69},[1724],{"nctId":1311,"briefTitle":1312,"status":142,"phases":1725,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1726,"interventions":1727},[59],[21],[1302,1319],{"trials":1729,"activeCount":69},[],{"trials":1731,"activeCount":69},[],{"trials":1733,"activeCount":69},[],{"intervention":1370,"totalTrials":81,"cells":1735},{"EARLY_PHASE1":1736,"PHASE1":1738,"PHASE2":1740,"PHASE3":1746,"PHASE4":1748,"NA":1750},{"trials":1737,"activeCount":69},[],{"trials":1739,"activeCount":69},[],{"trials":1741,"activeCount":69},[1742],{"nctId":1363,"briefTitle":1364,"status":142,"phases":1743,"primaryCompletion":229,"completion":229,"start":280,"enrollment":1089,"conditions":1744,"interventions":1745},[59],[21],[1368,1369,1370,1275],{"trials":1747,"activeCount":69},[],{"trials":1749,"activeCount":69},[],{"trials":1751,"activeCount":69},[],{"intervention":1224,"totalTrials":81,"cells":1753},{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1764,"PHASE4":1766,"NA":1768},{"trials":1755,"activeCount":69},[],{"trials":1757,"activeCount":69},[],{"trials":1759,"activeCount":69},[1760],{"nctId":1216,"briefTitle":1217,"status":142,"phases":1761,"primaryCompletion":1219,"completion":1219,"start":1220,"enrollment":1221,"conditions":1762,"interventions":1763},[59],[21],[1197,1224],{"trials":1765,"activeCount":69},[],{"trials":1767,"activeCount":69},[],{"trials":1769,"activeCount":69},[],{"intervention":1771,"totalTrials":81,"cells":1772},"FX005",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1774,"activeCount":69},[],{"trials":1776,"activeCount":69},[],{"trials":1778,"activeCount":69},[1779],{"nctId":1780,"briefTitle":1781,"status":142,"phases":1782,"primaryCompletion":270,"completion":989,"start":1783,"enrollment":262,"conditions":1784,"interventions":1785},"NCT01291914","Study of FX005 for the Treatment of Pain in Patients With Osteoarthritis of the Knee",[58,59],"2010-12",[399],[1771],{"trials":1787,"activeCount":69},[],{"trials":1789,"activeCount":69},[],{"trials":1791,"activeCount":69},[],{"intervention":86,"totalTrials":81,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1804,"PHASE4":1806,"NA":1808},{"trials":1795,"activeCount":69},[],{"trials":1797,"activeCount":69},[],{"trials":1799,"activeCount":69},[1800],{"nctId":75,"briefTitle":76,"status":77,"phases":1801,"primaryCompletion":79,"completion":79,"start":80,"enrollment":81,"conditions":1802,"interventions":1803},[59],[83],[85,86],{"trials":1805,"activeCount":69},[],{"trials":1807,"activeCount":69},[],{"trials":1809,"activeCount":69},[],{"intervention":1811,"totalTrials":81,"cells":1812},"Low Dose SKY0402",{"EARLY_PHASE1":1813,"PHASE1":1815,"PHASE2":1817,"PHASE3":1829,"PHASE4":1831,"NA":1833},{"trials":1814,"activeCount":69},[],{"trials":1816,"activeCount":69},[],{"trials":1818,"activeCount":69},[1819],{"nctId":1820,"briefTitle":1821,"status":77,"phases":1822,"primaryCompletion":471,"completion":471,"start":1823,"enrollment":34,"conditions":1824,"interventions":1825},"NCT00807209","Dose Finding Posterolateral Thoracotomy Study",[59],"2008-12",[15],[1811,1826,1827,1828],"High Dose SKY0402","Fentanyl via PCA","Bupivacaine via epidural",{"trials":1830,"activeCount":69},[],{"trials":1832,"activeCount":69},[],{"trials":1834,"activeCount":69},[],{"intervention":1826,"totalTrials":81,"cells":1836},{"EARLY_PHASE1":1837,"PHASE1":1839,"PHASE2":1841,"PHASE3":1847,"PHASE4":1849,"NA":1851},{"trials":1838,"activeCount":69},[],{"trials":1840,"activeCount":69},[],{"trials":1842,"activeCount":69},[1843],{"nctId":1820,"briefTitle":1821,"status":77,"phases":1844,"primaryCompletion":471,"completion":471,"start":1823,"enrollment":34,"conditions":1845,"interventions":1846},[59],[15],[1811,1826,1827,1828],{"trials":1848,"activeCount":69},[],{"trials":1850,"activeCount":69},[],{"trials":1852,"activeCount":69},[],{"intervention":1827,"totalTrials":81,"cells":1854},{"EARLY_PHASE1":1855,"PHASE1":1857,"PHASE2":1859,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1856,"activeCount":69},[],{"trials":1858,"activeCount":69},[],{"trials":1860,"activeCount":69},[1861],{"nctId":1820,"briefTitle":1821,"status":77,"phases":1862,"primaryCompletion":471,"completion":471,"start":1823,"enrollment":34,"conditions":1863,"interventions":1864},[59],[15],[1811,1826,1827,1828],{"trials":1866,"activeCount":69},[],{"trials":1868,"activeCount":69},[],{"trials":1870,"activeCount":69},[],{"intervention":1828,"totalTrials":81,"cells":1872},{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1874,"activeCount":69},[],{"trials":1876,"activeCount":69},[],{"trials":1878,"activeCount":69},[1879],{"nctId":1820,"briefTitle":1821,"status":77,"phases":1880,"primaryCompletion":471,"completion":471,"start":1823,"enrollment":34,"conditions":1881,"interventions":1882},[59],[15],[1811,1826,1827,1828],{"trials":1884,"activeCount":69},[],{"trials":1886,"activeCount":69},[],{"trials":1888,"activeCount":69},[],{"intervention":1890,"totalTrials":81,"cells":1891},"SKY0402 + bupivacaine HCl",{"EARLY_PHASE1":1892,"PHASE1":1894,"PHASE2":1896,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1893,"activeCount":69},[],{"trials":1895,"activeCount":69},[],{"trials":1897,"activeCount":69},[1898],{"nctId":1899,"briefTitle":1900,"status":142,"phases":1901,"primaryCompletion":453,"completion":1823,"start":1902,"enrollment":1903,"conditions":1904,"interventions":1905},"NCT01206608","Evaluation of the Safety and Efficacy of a Single Dose of SKY0402 in Subjects Undergoing Augmentation Mammoplasty",[59],"2008-03",40,[15],[1890,1906],"Mid-dose SKY0402 + bupivacaine HCl",{"trials":1908,"activeCount":69},[],{"trials":1910,"activeCount":69},[],{"trials":1912,"activeCount":69},[],{"intervention":1906,"totalTrials":81,"cells":1914},{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1925,"PHASE4":1927,"NA":1929},{"trials":1916,"activeCount":69},[],{"trials":1918,"activeCount":69},[],{"trials":1920,"activeCount":69},[1921],{"nctId":1899,"briefTitle":1900,"status":142,"phases":1922,"primaryCompletion":453,"completion":1823,"start":1902,"enrollment":1903,"conditions":1923,"interventions":1924},[59],[15],[1890,1906],{"trials":1926,"activeCount":69},[],{"trials":1928,"activeCount":69},[],{"trials":1930,"activeCount":69},[],{"intervention":1932,"totalTrials":81,"cells":1933},"DepoTXA",{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1950,"PHASE4":1952,"NA":1954},{"trials":1935,"activeCount":69},[],{"trials":1937,"activeCount":69},[],{"trials":1939,"activeCount":69},[1940],{"nctId":1941,"briefTitle":1942,"status":77,"phases":1943,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1263,"conditions":1946,"interventions":1948},"NCT02922582","Study of Local Administration of DepoTXA for Reduced Postsurgical Bleeding in Subjects Undergoing TKA",[59],"2017-11-27","2016-10-28",[1947],"Total Knee Arthroplasty",[1932,1949],"Tranexamic Acid",{"trials":1951,"activeCount":69},[],{"trials":1953,"activeCount":69},[],{"trials":1955,"activeCount":69},[],{"intervention":1949,"totalTrials":81,"cells":1957},{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1959,"activeCount":69},[],{"trials":1961,"activeCount":69},[],{"trials":1963,"activeCount":69},[1964],{"nctId":1941,"briefTitle":1942,"status":77,"phases":1965,"primaryCompletion":1944,"completion":1944,"start":1945,"enrollment":1263,"conditions":1966,"interventions":1967},[59],[1947],[1932,1949],{"trials":1969,"activeCount":69},[],{"trials":1971,"activeCount":69},[],{"trials":1973,"activeCount":69},[],{"intervention":348,"totalTrials":65,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1988,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1977,"activeCount":69},[],{"trials":1979,"activeCount":69},[1980,1984],{"nctId":340,"briefTitle":341,"status":142,"phases":1981,"primaryCompletion":343,"completion":343,"start":344,"enrollment":345,"conditions":1982,"interventions":1983},[58],[26],[348,265],{"nctId":530,"briefTitle":531,"status":142,"phases":1985,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":1986,"interventions":1987},[58],[538],[348,138],{"trials":1989,"activeCount":69},[],{"trials":1991,"activeCount":69},[],{"trials":1993,"activeCount":69},[],{"trials":1995,"activeCount":69},[],{"intervention":1997,"totalTrials":81,"cells":1998},"liposomal cytarabine",{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2015,"PHASE3":2017,"PHASE4":2019,"NA":2021},{"trials":2000,"activeCount":69},[],{"trials":2002,"activeCount":69},[2003],{"nctId":2004,"briefTitle":2005,"status":2006,"phases":2007,"start":2008,"enrollment":172,"conditions":2009,"interventions":2014},"NCT00003073","Chemotherapy in Treating Young Patients With Recurrent or Refractory Meningeal Leukemia, Lymphoma, or Solid Tumors","UNKNOWN",[58],"1997-02",[2010,2011,2012,2013],"Brain and Central Nervous System Tumors","Leukemia","Lymphoma","Unspecified Childhood Solid Tumor, Protocol Specific",[1997],{"trials":2016,"activeCount":69},[],{"trials":2018,"activeCount":69},[],{"trials":2020,"activeCount":69},[],{"trials":2022,"activeCount":69},[],{"intervention":2024,"totalTrials":81,"cells":2025},"SKY0402 300mg in healthy patients",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2038,"PHASE3":2040,"PHASE4":2042,"NA":2044},{"trials":2027,"activeCount":69},[],{"trials":2029,"activeCount":69},[2030],{"nctId":2031,"briefTitle":2032,"status":142,"phases":2033,"primaryCompletion":444,"completion":444,"start":488,"enrollment":1263,"conditions":2034,"interventions":2036},"NCT00812305","Hepatic Impairment Study: Pharmacokinetics in Healthy and Hepatically Impaired Subjects",[58],[18,2035],"Hepatic Impairment",[2024,2037],"SKY0402 300mg in hepatically impaired patients",{"trials":2039,"activeCount":69},[],{"trials":2041,"activeCount":69},[],{"trials":2043,"activeCount":69},[],{"trials":2045,"activeCount":69},[],{"intervention":2037,"totalTrials":81,"cells":2047},{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2056,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2049,"activeCount":69},[],{"trials":2051,"activeCount":69},[2052],{"nctId":2031,"briefTitle":2032,"status":142,"phases":2053,"primaryCompletion":444,"completion":444,"start":488,"enrollment":1263,"conditions":2054,"interventions":2055},[58],[18,2035],[2024,2037],{"trials":2057,"activeCount":69},[],{"trials":2059,"activeCount":69},[],{"trials":2061,"activeCount":69},[],{"trials":2063,"activeCount":69},[],{"intervention":358,"totalTrials":81,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2074,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2067,"activeCount":69},[],{"trials":2069,"activeCount":69},[2070],{"nctId":350,"briefTitle":351,"status":142,"phases":2071,"primaryCompletion":353,"completion":353,"start":354,"enrollment":355,"conditions":2072,"interventions":2073},[58],[136],[358,265],{"trials":2075,"activeCount":69},[],{"trials":2077,"activeCount":69},[],{"trials":2079,"activeCount":69},[],{"trials":2081,"activeCount":69},[],{"intervention":1137,"totalTrials":81,"cells":2083},{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2092,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2085,"activeCount":69},[],{"trials":2087,"activeCount":69},[2088],{"nctId":1131,"briefTitle":1132,"status":142,"phases":2089,"primaryCompletion":1134,"completion":1134,"start":445,"enrollment":162,"conditions":2090,"interventions":2091},[58],[15],[429,1137],{"trials":2093,"activeCount":69},[],{"trials":2095,"activeCount":69},[],{"trials":2097,"activeCount":69},[],{"trials":2099,"activeCount":69},[],{"intervention":1402,"totalTrials":81,"cells":2101},{"EARLY_PHASE1":2102,"PHASE1":2104,"PHASE2":2110,"PHASE3":2112,"PHASE4":2114,"NA":2116},{"trials":2103,"activeCount":69},[],{"trials":2105,"activeCount":69},[2106],{"nctId":1392,"briefTitle":1393,"status":142,"phases":2107,"primaryCompletion":1395,"completion":1396,"start":1397,"enrollment":1398,"conditions":2108,"interventions":2109},[58],[1400,26],[1402,1328],{"trials":2111,"activeCount":69},[],{"trials":2113,"activeCount":69},[],{"trials":2115,"activeCount":69},[],{"trials":2117,"activeCount":69},[],{"intervention":2119,"totalTrials":81,"cells":2120},"Questionnaire and Physical Exam",{"EARLY_PHASE1":2121,"PHASE1":2123,"PHASE2":2125,"PHASE3":2127,"PHASE4":2129,"NA":2131},{"trials":2122,"activeCount":69},[],{"trials":2124,"activeCount":69},[],{"trials":2126,"activeCount":69},[],{"trials":2128,"activeCount":69},[],{"trials":2130,"activeCount":69},[],{"trials":2132,"activeCount":69},[2133],{"nctId":2134,"briefTitle":2135,"status":142,"phases":2136,"primaryCompletion":2137,"completion":2137,"start":2138,"enrollment":2139,"conditions":2140,"interventions":2141},"NCT01076686","Observational Study to Assess Long-Term Follow-Up of Breast Augmentation Subjects",[],"2010-03","2010-02",94,[15],[2119]]